Finance

Lists
Why is INO down २.०५%?
Dive Deeper
INO:NASDAQ
Inovio Pharmaceuticals Inc
US$ १.४३
-२.०५%
(-०.०३०) 1D
नोभेम्बर १३, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Open
US$ १.४४
High
US$ १.४८
Low
US$ १.३९
Mkt. cap
२६.७८ करोड
Avg. vol.
१.९३ करोड
Volume
५२.१९ लाख
52-wk high
US$ २.७२
52-wk low
US$ ०.५७
EPS
-US$ ०.८०
Beta
१.७१
Shares outstanding
१८.७३ करोड
No. of employees
११२
Open
US$ १.४४
High
US$ १.४८
Low
US$ १.३९
Mkt. cap
२६.७८ करोड
Avg. vol.
१.९३ करोड
Volume
५२.१९ लाख
52-wk high
US$ २.७२
52-wk low
US$ ०.५७
EPS
-US$ ०.८०
Beta
१.७१
Shares outstanding
१८.७३ करोड
No. of employees
११२
News stories
From web sources and news partners
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees११२
Founded१९९९
Headquarters-
SectorHealth Care
Industry-
Websiteinovio.com
Analyst ratings
Based on 3 analysts giving stock ratings to INO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current US$ १.४३
US$ ८.०० (+४५९.४४%)
Average
US$ ६.३३ (+३४२.६६%)
Lowest
US$ ५.०० (+२४९.६५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$ ५.००
+२४९.७%
11/12/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
US$ ६.००
+३१९.६%
11/11/2026
Roger Song
Jefferies
Buy
Reiterated
US$ ८.००
+४५९.४%
11/06/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
US$ १३.००
+८०९.१%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
२.९९ लाख
Cost of goods sold
१.०३ करोड
१.४१ करोड
१.०८ करोड
-
Cost of revenue
१.०३ करोड
१.४१ करोड
१.०८ करोड
-
Research and development expenses
-
-
-
१.०६ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७२.१५ लाख
७८.८० लाख
७७.९८ लाख
९२.०६ लाख
Operating expense
७२.१५ लाख
७८.८० लाख
७७.९८ लाख
१.९८ करोड
Total operating expenses
१.७५ करोड
२.१९ करोड
१.८६ करोड
१.९८ करोड
Operating income
-१.७५ करोड
-२.१९ करोड
-१.८६ करोड
-१.९५ करोड
Other non operating income
२.१२ करोड
४१.३७ लाख
१.२७ करोड
-३.०२ करोड
EBT including unusual items
३७.६५ लाख
-१.९७ करोड
-६०.१२ लाख
-४.९२ करोड
EBT excluding unusual items
३७.५५ लाख
-१.९५ करोड
-५५.३३ लाख
-४.९३ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
३७.६५ लाख
-१.९७ करोड
-६०.१२ लाख
-४.९२ करोड
Net profit margin
-
-
-
-१६,४६१.९०%
Earnings per share
-०.२८
-०.३१
-०.२४
-०.२३
Interest and investment income
४.४९ लाख
४.४० लाख
३.६४ लाख
३.५६ लाख
Interest expense
-
-
-
-
Net interest expenses
४.४९ लाख
४.४० लाख
३.६४ लाख
३.५६ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.७१ करोड
-२.१६ करोड
-१.८३ करोड
-१.९२ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू